Price
5,425
-0.07%52W Range
Market Cap
₹64,864.01 Cr
Traded: ₹79.53 Cr (0.12%) 0.0x
Free Float: ₹3,593.47 Cr (2.21% of FF traded)
Volume · 60D trend
1.46 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +12.0% | +11.0% | +8.0% | -- | +13.0% | Stable |
| Profit | +12.0% | +9.0% | +32.0% | -- | +13.0% | Stable |
| Return | +16.0% | +13.0% | +18.0% | +4.0% | -- | Stable |
| ROE | +18.0% | +18.0% | +19.0% | -- | -- | Stable |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,603 | 3,737 | 4,001 | 3,371 | 3,144 | 3,374 | 3,415 | 3,032 | 2,936 | 3,324 | 3,440 | 2,968 | 2,903 | 3,041 | 3,079 |
| Expenses | 3,086 | 2,909 | 3,080 | 2,632 | 2,752 | 2,615 | 2,662 | 2,423 | 2,534 | 2,616 | 2,693 | 2,579 | 2,549 | 2,442 | 2,625 |
| Operating Profit | 517 | 828 | 921 | 739 | 391 | 759 | 753 | 609 | 402 | 708 | 747 | 389 | 353 | 599 | 454 |
| OPM % | 14.0% | 22.0% | 23.0% | 22.0% | 12.0% | 23.0% | 22.0% | 20.0% | 14.0% | 21.0% | 22.0% | 13.0% | 12.0% | 20.0% | 15.0% |
| Other Income | 65 | 90 | 104 | 149 | 146 | 93 | 134 | 120 | 76 | 42 | 6 | 66 | -34 | 45 | 51 |
| Interest | 54 | 42 | 35 | 30 | 28 | 36 | 28 | 29 | 27 | 25 | 30 | 30 | 29 | 27 | 25 |
| Depreciation | 106 | 95 | 94 | 88 | 112 | 85 | 79 | 80 | 83 | 70 | 74 | 72 | 78 | 78 | 77 |
| Profit Before Tax | 423 | 781 | 896 | 771 | 396 | 731 | 780 | 619 | 367 | 655 | 648 | 353 | 212 | 539 | 402 |
| Tax % | 40.0% | 16.0% | 13.0% | 13.0% | 18.0% | 12.0% | 10.0% | 11.0% | 17.0% | 8.0% | 5.0% | 18.0% | 68.0% | 15.0% | 14.0% |
| Net Profit | 251 | 653 | 779 | 668 | 322 | 641 | 702 | 550 | 304 | 604 | 615 | 288 | 68 | 460 | 348 |
| Exceptional Items | -135 | -53 | 0 | 13 | 0 | 0 | 0 | 0 | -13 | -51 | -58 | 0 | -103 | 0 | 0 |
| EPS (Rs) | 19.8 | 53.2 | 64.0 | 55.6 | 25.6 | 52.3 | 57.6 | 45.6 | 24.6 | 49.8 | 51.9 | 24.0 | 5.9 | 38.0 | 27.7 |
| Sales Growth (YoY) | 14.6% | 10.8% | 17.2% | 11.2% | 7.1% | 1.5% | -0.7% | 2.2% | 1.1% | 9.3% | 11.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -3.6% | -6.6% | 18.7% | 7.2% | -6.8% | -1.2% | 12.6% | 3.3% | -11.7% | -3.4% | 15.9% | 2.2% | -4.5% | -1.2% | -- |
| OP Growth (YoY) | 32.2% | 9.1% | 22.3% | 21.3% | -2.7% | 7.2% | 0.8% | 56.6% | 13.9% | 18.2% | 64.5% | -- | -- | -- | -- |
| OP Growth (QoQ) | -37.6% | -10.1% | 24.6% | 89.0% | -48.5% | 0.8% | 23.6% | 51.5% | -43.2% | -5.2% | 92.0% | 10.2% | -41.1% | 31.9% | -- |
| Profit Growth (YoY) | 2.0% | 8.0% | 11.0% | 20.0% | 1.0% | -2.0% | 4.0% | 90.0% | 191.0% | 40.0% | 101.0% | 125.0% | -9.0% | -14.0% | -39.0% |
| EPS Growth (YoY) | -22.7% | 1.6% | 11.1% | 21.8% | 4.2% | 5.2% | 11.0% | 90.2% | 313.3% | 30.8% | 87.6% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -62.8% | -16.9% | 15.2% | 117.2% | -51.1% | -9.1% | 26.3% | 85.7% | -50.7% | -4.1% | 116.4% | 303.7% | -84.4% | 37.4% | -- |
| OP Margin | 14.3% | 22.2% | 23.0% | 21.9% | 12.4% | 22.5% | 22.1% | 20.1% | 13.7% | 21.3% | 21.7% | 13.1% | 12.2% | 19.7% | 14.8% |
| Net Margin | 7.0% | 17.5% | 19.5% | 19.8% | 10.2% | 19.0% | 20.6% | 18.1% | 10.3% | 18.2% | 17.9% | 9.7% | 2.3% | 15.1% | 11.3% |
| Material Cost % | 34.6% | 34.1% | 35.0% | 34.7% | 40.7% | 35.7% | 35.3% | 35.5% | 37.7% | 39.3% | 38.6% | 40.4% | 43.3% | 41.1% | 42.4% |
| Employee Cost % | 19.8% | 19.3% | 17.8% | 20.6% | 19.6% | 18.5% | 17.9% | 19.9% | 17.2% | 17.2% | 16.1% | 19.1% | 17.3% | 17.3% | 18.5% |
| P/S | 4.41 | 4.57 | 4.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 28.18 | 27.49 | 28.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 4.69 | 4.88 | 5.05 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please Find Attached herewith intimation regarding Closure of Trading Window.
Please find attached herewith Analyst / Investor Meet - Intimation.
Please find attached herewith Analyst / Investor Meet - Intimation.
Please Find Attached herewith Press Release.
Please find Attached herewith Q4 FY26- Earnings Call Transcript.
Attached please find herewith newspaper advertisement
Please Find Attached Herewith the Annual Secretarial Compliance Certificate for the Financial Year ended 31.03.2026.
Pl find enclosed herewith the outcome of the BM dated 28th May, 2026. The meeting of the Board of Directors of the Company commenced at 11.20 am and concluded at 13.15 pm.
The BOD at its meeting held today approved the reappointment of Mrs Madhurima Singh as Executive Director for a term of 5 consecutive years wef 20th Dec, 26.
Pl find enclosed Audited Financial Results along with auditors report for FY ended 31st march 26
Pl find enclosed press release and analyst presentation on Q4 and FY26 earnings and business updates of the Company.
The BOD at its meeting held today has recommended a final dividend of Rs. 10 per equity share of Rs. 2 each for FY ended 31st March 26 for approval of the shareholders of the Company at ....
The Financial Results of the Company for the quarter and year ended 31st march, 2026 having communicated to the Stock Exchanges today ie 28th May , the trading window shall open on 1st June, 26.
The BOD at its meeting held today has fixed 7th Aug as the record date for payment of final dividend and 20th Aug as the cut off for AGM.
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the '' Q4FY26 and FY2026 Earnings Conference Call'' ....
Please find enclosed herewith the details of the Analyst / Investor meeting to be held on 29th May,2026.
Please find attached herewith Intimation of Conference Call of Q4FY26 and FY26 Financial Result.
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve (i) The Standalone and Consolidated ....
Please find Attached herewith Intimation regarding Appointment of Senior Management Personnel.
This is to Inform you regarding US FDA inspection conducted today at the Company'' s CRO facility located at Taloja.
Please find Attached herewith Disclosure under Regulation 30 of SEBI(LODR) 2015.
Please find attached herewith Intimation about US FDA Inspection at Company'' s manufacturing facility located at Amaliya, Daman.
Please find attached herewith intimation for Change in Key Managerial Personnel - Resignation of Chief Executive Officer
Please find attached herewith intimation in respect of an order passed by Statutory Authority under the Income Tax Act, 1961
Please find Attached herewith Intimation for Incorporation of Wholly owned subsidiary of the Company.
Please find attached herewith Press release- Alkem Launches A to Z Daily, an everyday multivitamin supplement for body and mind.
Please find attached herewith intimation about increase in investment to be made for setting up of manufacturing facility of the Company in Ujjain, Madhya Pradesh.
Please find attached herewith Intimation regarding change in Senior Management.
Please Find Attached herewith Intimation for Incorporation of Wholly Owned Subsidiary of the Company as a ''Scientific Office''.
Please find attached herewith Intimation regarding Closure of Trading Window.
This is to inform you that Mr. Samsher Kumar Deo has been appointed as Senior Management Position in the Company effective from 27th March,2026
Please find attached herewith Press release on Alkem launches Semaglutide injection in India, with weekly therapy starting at INR 450/-
Please find enclosed herewith the details of the Analyst / Investor meeting to be held on 26th March,2026.
Please find attached herewith Intimation regarding receipt of EU GMP Certificate for the Company manufacturing facility located at Daman, India.
Please find attached herewith intimation regarding allotment of land for setting up of a greenfield formulations manufacturing facility of the Company in Ujjain, Madhya Pradesh.
Please find attached herewith Intimation regarding receipt of EU GMP Certificate for the Company manufacturing facility located at Baddi, India.
Please find attached herewith update on Acquisition.
Please find attached herewith Investor meet on Alkem MedTech''s strategic way forward- video Recording.
Please find attached herewith updated Investor meet Presentation on Alkem MedTech ''s strategic way forward.
Please find attached herewith Schedule of Analyst/Investor Meetings.
Please find attached herewith Q3 FY26- Earnings Call Transcript.
Enclosed please find herewith investor meet presentation on Alkem MedTech''s strategic way forward
Enclosed please find updated disclosure with regards to closure of USFDA inspection at the manufacturing facility of Enzene Biosciences Limited, a subsidiary of the Company in India located ....
Enclosed please find herewith newspaper publication.
Enclosed please find herewith disclosure with regards to closure USFDA inspection at the manufacturing facility of Enzene Biosciences Limited, a subsidiary of the Company in India
In continuation of our letter dated 23rd Jan, 2026, the BOD at its meeting held today 13th Feb has declared interim dividend of Rs.43 per equity share on face value of Rs. 2 per share for Fy 25-26.
Please find enclosed herewith the details of the Analyst / Investor meeting.
Please find attached herewith Newspaper Publication informing the record date fixed Interim Dividend for 2025-2026.
Please find attached herewith Newspaper Publication informing the record date fixed Interim Dividend for 2025-2026.
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the '' Q3 & 9MFY26 Earnings Conference Call'' is ....
Annual Reports
13Credit Ratings
6Concalls
49Feb 2026
28 Feb 2026Feb 2026
28 Feb 2026Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Mar 2025
31 Mar 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Sep 2024
30 Sept 2024Aug 2024
31 Aug 2024Jun 2024
30 Jun 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Aug 2020
31 Aug 2020Aug 2020
31 Aug 2020Jun 2020
30 Jun 2020Jun 2020
30 Jun 2020Feb 2020
29 Feb 2020Nov 2019
30 Nov 2019Aug 2019
31 Aug 2019May 2019
31 May 2019Feb 2019
28 Feb 2019Oct 2018
31 Oct 2018Jul 2018
31 Jul 2018May 2018
31 May 2018Feb 2018
28 Feb 2018Feb 2018
28 Feb 2018Nov 2017
30 Nov 2017Aug 2017
31 Aug 2017May 2017
31 May 2017Jan 2017
31 Jan 2017Nov 2016
30 Nov 2016Aug 2016
31 Aug 2016May 2016
31 May 2016Feb 2016
29 Feb 2016Held by ETFs
37 ETFs hold ALKEM · sorted by weight
Held by Mutual Funds
7 schemes hold ALKEM · sorted by weight